Hematologic Malignancy
Myelodysplastic Syndrome
CI-CAN-00001247MDN · MDSExplore in graph →
Hematologic336 active trials3 approved drugs14 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001247MDN · MDSExplore in graph →
Clinical trials
1,702 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (307)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04365179 | Study of NEROFE, a Novel Hormone-Peptide in Adult Patients With Advanced MDS and AML | unknown | Phase 1 | 18 | Immune System Key LtdINDUSTRY | 1 | Jul 10, 2024 | clinicaltrials |
| NCT02061800 | CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant | unknown | Phase 1 / Phase 2 | 14 | Diane GeorgeOTHER | 1 | Jun 4, 2024 | clinicaltrials |
| Sirolimus+Abatacept+Mycophenolate Mofetil for Prophylaxis of aGVHD in Patients Receiving Haplo-HSCT Who Are Intolerant to Calcineurin Inhibitors |
| unknown |
| Phase 1 / Phase 2 |
| 6 |
| Peking University People's HospitalOTHER |
| 0 |
| Mar 21, 2024 |
| clinicaltrials |
| NCT03291444 | CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS | unknown | Phase 1 | 30 | Zhujiang HospitalOTHER | 1 | Mar 15, 2024 | clinicaltrials |
| NCT04358393 | A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS | unknown | Phase 1 / Phase 2 | 69 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Feb 1, 2024 | clinicaltrials |
| NCT06218771 | A Study of TQB3454 Tablets in Patients With Blood Tumors | unknown | Phase 1 / Phase 2 | 80 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jan 23, 2024 | clinicaltrials |
| NCT04284228 | Antigen-specific T Cell Therapy for AML or MDS Patients With Relapsed Disease After Allo-HCT | unknown | Phase 1 / Phase 2 | 22 | NexImmune Inc.INDUSTRY | 1 | Jan 16, 2024 | clinicaltrials |
| NCT06008405 | Clinical Trial Evaluating the Safety of the TQB2928 Injection Combination Therapy | unknown | Phase 1 | 48 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Sep 6, 2023 | clinicaltrials |
| NCT05005299 | Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell Transplantation(VICTORY) | unknown | Phase 1 | 18 | Melbourne HealthOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT05970822 | Study of BC3402 in Combination With Azacitidine in Patients With MDS and CMML | unknown | Phase 1 | 32 | Biocity Biopharmaceutics Co., Ltd.INDUSTRY | 1 | Aug 1, 2023 | clinicaltrials |
| NCT05140811 | A Study of IMM01 Combined With Azacitidine in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome | unknown | Phase 1 / Phase 2 | 126 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc.OTHER | 1 | May 24, 2023 | clinicaltrials |
| NCT05448599 | A Clinical Study of 6MW3211 Monotherapy or Combination Therapy for AML or MDS | unknown | Phase 1 / Phase 2 | 120 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 1 | Mar 15, 2023 | clinicaltrials |
| NCT05740917 | To Evaluate the Phase I Clinical Study of XZB-0004 in Patients With AML and MDS | unknown | Phase 1 | 82 | Xuanzhu Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Feb 23, 2023 | clinicaltrials |
| NCT03855371 | Mutant p53-based Personalized Trial Using Decitabine and Arsenic Trioxide on AML/MDS(PANDA-T0) | unknown | Phase 1 | 5 | Ruijin HospitalOTHER | 1 | Nov 4, 2022 | clinicaltrials |
| NCT02752243 | CIK-Cells in Relapsing Patients With Acute Leukemia or Myelodysplastic Syndromes After SCT. | unknown | Phase 1 / Phase 2 | 32 | Peter BaderOTHER | 1 | Apr 1, 2022 | clinicaltrials |
| NCT04764513 | Safety and Efficiency of γδ T Cell Against Hematological Malignancies After Allo-HSCT | unknown | Phase 1 / Phase 2 | 20 | Chinese PLA General HospitalOTHER | 1 | Mar 28, 2022 | clinicaltrials |
| NCT03647800 | Study of APVO436 in Patients With AML or MDS | unknown | Phase 1 | 136 | Aptevo Research and Development LLCINDUSTRY | 1 | Feb 10, 2022 | clinicaltrials |
| NCT05066958 | Ex-vivo Primed Memory Donor Lymphocyte Infusion to Boost Anti-viral Immunity After T-cell Depleted HSCT | unknown | Phase 1 / Phase 2 | 20 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Oct 4, 2021 | clinicaltrials |
| NCT04743115 | A Phase I, Open-Label, Dose Escalation and Cohort Expansion Study of BS HH 002.SA in Patients With AML and MDS | unknown | Phase 1 | 66 | Shanghai Bensen Pharmaceutical Co., Ltd.INDUSTRY | 0 | Feb 8, 2021 | clinicaltrials |
| NCT03083054 | Cellular Immunotherapy for Patients With High Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia | unknown | Phase 1 / Phase 2 | 5 | University of Campinas, BrazilOTHER | 1 | Oct 12, 2020 | clinicaltrials |
| NCT01619761 | NK Cells in Cord Blood Transplantation | unknown | Phase 1 | 13 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 11, 2020 | clinicaltrials |
| NCT03836690 | Transfer of Effector Memory T Cells (Tem) Following Allogeneic Stem Cell Transplantation(ToTem) | unknown | Phase 1 | 18 | University College, LondonOTHER | 1 | Oct 25, 2019 | clinicaltrials |
| NCT01211457 | Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS) | unknown | Phase 1 / Phase 2 | 65 | Cyclacel Pharmaceuticals, Inc.INDUSTRY | 1 | Jul 16, 2019 | clinicaltrials |
| NCT02123836 | Natural Killer Cells in Acute Leukaemia and Myelodysplastic Syndrome | unknown | Phase 1 | 20 | National University Hospital, SingaporeOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT02717884 | Study of Sensitization of Non-M3 AML Blasts to ATRA by Epigenetic Treatment With Tranylcypromine (TCP)(TRANSATRA) | unknown | Phase 1 / Phase 2 | 60 | Michael LuebbertOTHER | 1 | Oct 18, 2018 | clinicaltrials |
| NCT02576301 | Dose Escalation of OXi4503 as Single Agent and Combination With Cytarabine w/Subsequent Ph 2 Cohorts for AML and MDS(AML) | unknown | Phase 1 / Phase 2 | 105 | Mateon TherapeuticsINDUSTRY | 1 | Jun 4, 2018 | clinicaltrials |
| NCT01451268 | Phase I/II Study With Oral Panobinostat Maintenance Therapy Following Allogeneic Stem Cell Transplantation in Patients With High Risk Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)(PANOBEST) | unknown | Phase 1 / Phase 2 | 62 | Johann Wolfgang Goethe University HospitalOTHER | 1 | Mar 20, 2018 | clinicaltrials |
| NCT03091933 | Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion)(GLIDE) | unknown | Phase 1 / Phase 2 | 20 | Ciusss de L'Est de l'Île de MontréalOTHER | 1 | Dec 6, 2017 | clinicaltrials |
| NCT02493829 | B7.1/IL-2 Leukaemia Cell Vaccine for Non-Transplant AML RFUSIN2-AML2 (NTX) | unknown | Phase 1 | 10 | King's College LondonOTHER | 0 | Apr 13, 2017 | clinicaltrials |
| NCT02240537 | Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic Cancer(BBMPI03) | unknown | Phase 1 | 4 | Benovus Bio, Inc.INDUSTRY | 1 | Apr 19, 2016 | clinicaltrials |
| NCT01277484 | Dose Finding Study of Post-BMT Decitabine Maintenance Treatment in Higher-risk MDS and MDS/AML(PODAC) | unknown | Phase 1 | 19 | Seoul St. Mary's HospitalOTHER | 1 | Nov 20, 2015 | clinicaltrials |
| NCT02007811 | Open-label Clinical Trial to Investigate the Safety and Tolerability of Allogeneic B-cell Concentrates for Immune Reconstitution After Allogeneic Stem Cell Transplantation Measured as Response to a Antedated Single Vaccination(B-cell therapy) | unknown | Phase 1 / Phase 2 | 15 | University of Erlangen-Nürnberg Medical SchoolOTHER | 1 | Mar 26, 2014 | clinicaltrials |
| NCT00242515 | T-cell Depleted Donor Lymphocyte Infusion (DLI)for Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS) | unknown | Phase 1 / Phase 2 | 16 | National University Hospital, SingaporeOTHER | 1 | Jan 8, 2014 | clinicaltrials |
| NCT00004036 | Combination Chemotherapy Plus Amifostine in Treating Patients With Advanced Cancer | unknown | Phase 1 | 30 | The Cleveland ClinicOTHER | 1 | Dec 19, 2013 | clinicaltrials |
| NCT01983761 | Study of ASC-101 in Patients With Hematologic Malignancies Who Receive Dual-cord Umbilical Cord Blood Transplantation | unknown | Phase 1 / Phase 2 | 25 | Targazyme, Inc.INDUSTRY | 1 | Nov 18, 2013 | clinicaltrials |
| NCT01716364 | Safety Study of Anti LewisY Chimeric Antigen Receptor in Myeloma, Acute Myeloid Leukemia or Myelodysplastic Syndrome | unknown | Phase 1 | 6 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Dec 4, 2012 | clinicaltrials |
| NCT00838240 | Clofarabine, Cytarabine, and Idarubicin in Treating Patients With Intermediate-Risk or High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplasia(AML-14A) | unknown | Phase 1 / Phase 2 | 114 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 5 | Jul 20, 2012 | clinicaltrials |
| NCT01509300 | HLA-haploidentical Hematopoietic Stem Cell Transplantation for Children and Adolescents With Acute Leukemia, Myelodysplastic Syndrome and Solid Tumors | unknown | Phase 1 / Phase 2 | 10 | Asan Medical CenterOTHER | 1 | Jan 13, 2012 | clinicaltrials |
Data updated 22 days agoSource updated Jul 10, 2024source: clinicaltrials